Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

ApolloBio and Inovio Alter $43 Million China Deal for HPV Immunotherapy

publication date: Jan 3, 2018

ApolloBio, a Beijing company focused on cancer, has amended its year-old deal to acquire China rights to Inovio's DNA immunotherapy aimed at pre-cancers caused by human papillomavirus (HPV). Under the new terms, ApolloBio will pay $23 million upfront (previously: $15 million) and $20 million (unchanged) in milestones, plus double-digit tiered royalties on sales. Also, ApolloBio will not purchase $35 million in Inovio stock. As before, the agreement gives ApolloBio the right to develop and commercialize VGX-3100 in greater China. More details....

Stock Symbols: (NEEQ: 430187) (NSDQ: INO)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Click here to join.